Current Environment: Production

Warning

An important message to our patients and their caregivers.

We are here for you. Read more

Summary

The purpose of this study is to evaluate the efficacy, safety, pharmacodynamic (PD) and pharmacokinetic (PK) effect of VX-561.

Conditions

Cystic Fibrosis

Recruitment Status

COMPLETED

Eligibility Criteria

Key Inclusion Criteria:

* Must have 1 of the following 9 CFTR mutations on at least 1 allele: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, or G1349D
* On ivacaftor therapy
* FEV1 value ≥40% and ≤100% of predicted mean for age, sex, and height

Key Exclusion Criteria:

* History of clinically significant cirrhosis with or without portal hypertension
* History of solid organ or hematological transplantation
* Lung infection with organisms associated with a more rapid decline in pulmonary status

Other protocol defined Inclusion/Exclusion criteria may apply

Intervention

Intervention Type

Intervention Name

DRUG

VX-561

DRUG

IVA

DRUG

Placebo

DRUG

Placebo

Phase

PHASE2

Gender

ALL

Min Age

18 Years

Max Age

N/A

Download Date

2022-01-25

Principal Investigator

N/A

Primary Contact Information

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team:

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis NCT03911713